Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Cologne
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06419179CT.gov Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | — | Enrolling By Invitation | — | — | — |
NCT06217757CT.gov Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | — | Recruiting | — | — | — |
NCT05975944CT.gov Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05411679CT.gov EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05623319CT.gov Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) | — | Recruiting | — | — | — |
NCT05245994CT.gov An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | — | Unknown | — | — | — |
NCT04538378CT.gov Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors | — | Terminated | — | — | — |
NCT04728230CT.gov Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | — | Active Not Recruiting | — | — | — |
NCT04624204CT.gov Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | — | Active Not Recruiting | — | — | — |
NCT03923270CT.gov Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
Show 10 more trialsShow fewer
NCT03428607CT.gov Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | — | Completed | — | — | — |
NCT03532880CT.gov A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02899728CT.gov Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02937818CT.gov A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT02498613CT.gov A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03009682CT.gov Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations | — | Completed | — | — | — |
NCT02769962CT.gov Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02734004CT.gov A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | — | Active Not Recruiting | — | — | — |
NCT02446704CT.gov Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | — | Unknown | — | — | — |
NCT02511795CT.gov AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | University of Cologne | P3 | B · 62 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Nogitecan | AbbVie | P4 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →